Prevention and Treatment of Peritoneal Dialysis-Related Infections

Evidence-Based Nephrology

Volumn , Issue , 2009, Pages 509-532

  Strippoli, Giovanni F M ^a   Wiggins, Kathryn J ^b   Johnson, David W ^c   Navaneethan, Sankar ^d   Cancarini, Giovanni ^e   Craig, Jonathan C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNITY HEALTH SYSTEM   (United States)

^e SPEDALI CIVILI   (Italy)

Author keywords

Caring for Australians with Renal Impairment CARI ); End stage renal disease (ESRD); Exit site and tunnel infections; Gram stain and culture; PD modality (continuous ambulatory PD CAPD or automated PD APD ) affecting peritonitis rates; PD related infections; Treatment of peritonitis

Indexed keywords

EID: 67649330414     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303391.ch47     Document Type: Chapter

References (83)

1. Heaf J. Underutilization of peritoneal dialysis. JAMA 2004; 291(6): 740-742.
2. Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999-2002). Nephrol Dial Transplant 2004; 19(10): 2584-2591.
3. CARI Guidelines (Caring for Australians with Renal Impairment). Nephrology (Carlton) 2005; 9(Suppl 3):S1-S106.
4. Grunberg J, Verocay MC, Rebori A, Ramela V, Amaral C, Hekimian G et al. Twentyyears' pediatric chronic peritoneal dialysis in Uruguay:patient and technique survival. Pediatr Nephrol 2005; 20(9): 1315-1319.
5. Katz IJ, Sofianou L, Hopley M. An African community-based chronicam-bulatory peritoneal dialysis programme. Nephrol Dial Transplant 2001; 16(12): 2395-2400.
6. Vas S, Oreopoulos DG. Infections in patients undergoing peritoneal dialysis. Infect Dis Clin North Am 2001; 15(3): 743-774.
7. Oxton LL, Zimmerman SW, Roecker EB, Wakeen M. Risk factors for peritoneal dialysis-related infections. Perit Dial Int 1994; 14(2): 137-144.
8. Salusky I, Holloway M. Selection of peritoneal dialysis for pediatric patients. Perit Dial Int 1994; 17(3): S35-S37.
9. Juergensen PH, Gorban-Brennan N, Troidle L, Finkelstein FO. Racial differences and peritonitis in an urban peritoneal dialysis center. Adv Perit Dial 2002; 18: 117-118.
10. Lim WH, Johnson DW, McDonald SP. Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia:analysis of ANZDATA. Nephrology (Carlton) 2005; 10(2):192-197.
11. McDonald SP, Collins JF, Rumpsfeld M, Johnson DW. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int 2004; 24(4): 340-346.
12. Alves FR, Dantas RC, Lugon JR. Higher incidence of catheter-related infections in a tropical climate. Adv Perit Dial 1993; 9: 244-247.
13. Szeto CC, Chow KM, Wong TY, Leung CB, Li PK. Influence of climate on the incidence of peritoneal dialysis-related peritonitis. Perit Dial Int 2003; 23(6): 580-586.
14. Troidle L, Watnick S, Wuerth DB, Gorban-Brennan N, Kliger AS, Finkel-stein FO. Depression and its association with peritonitis in long-term peritoneal dialysis patients. Am J Kidney Dis 2003; 42(2): 350-354.
15. Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett DK, Hamilton RW et al. Risk factors for peritonitis in long-term peritoneal dialysis:the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Am J Kidney Dis 1996; 28(3): 428-436.
16. Schaefer F. Management of peritonitis in children receiving chronic peritoneal dialysis. Paediatr Drugs 2003; 5(5): 315-325.
17. Huang JW, Hung KY, Yen CJ, Wu KD, Tsai TJ. Comparison of infectious complications in peritoneal dialysis patients using either a twin-bag system or automated peritoneal dialysis. Nephrol Dial Transplant 2001; 16(3): 604-607.
18. Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the United States Renal Data System database:CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis 2005; 45(2): 372-380.
19. Churchill DN, Thorpe KE, Vonesh EF, Keshaviah PR. Lower probabilityof patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1997; 8(6): 965-971.
20. Piraino B. Staphylococcus aureus infections in dialysis patients:focus on prevention. ASAIO J 2000; 46(6): S13-S17.
21. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7(10): 2176-2182.
22. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics:the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11(3): 498-506.
23. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4): S39-S47.
24. Rigby RJ, Hawley CM. Sclerosing peritonitis:the experience in Australia. Nephrol Dial Transplant 1998; 13(1): 154-159.
25. Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis. Adv Perit Dial 2000; 16: 257-261.
26. Piraino B. ADEMEX:how should it change our practice? Adequacy of Peritoneal Dialysis in Mexico. Perit Dial Int 2002; 22(5): 552-554.
27. Burkart JM. Recommendations for clinical practice and research needs directed at reducing morbidity and mortality in peritoneal dialysis. Perit Dial Int 1997; 17(Suppl 3): S6-S8.
28. Luzar MA, Brown CB, Balf D, Hill L, Issad B, Monnier B et al. Exit-site care and exit-site infection in continuous ambulatoryperitoneal dialysis (CAPD):results of a randomized multicenter trial. Perit Dial Int 1990; 10(1): 25-29.
29. Peacock SJ, Mandal S, Bowler IC. Preventing Staphylococcus aureus infection in the renal unit. QJM 2002; 95(6): 405M10.
30. Piraino B. Infectious complications of peritoneal dialysis. Perit Dial Int 1997; 17(Suppl 3): S15-S18.
31. Pickering SJ, Fleming SJ, Bowley JA, Sissons P, Oppenheim BA, Burnie J et al. Urokinase:a treatment for relapsing peritonitis due to coagulase-negative staphylococci. Nephrol Dial Transplant 1989; 4(1): 62-65.
32. Innes A, Burden RP, Finch RG, Morgan AG. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase:a double-blind clinical trial. Nephrol Dial Transplant 1994; 9(7): 797-799.
33. Ejlersen E, Brandi L, Lokkegaard H, Ladefoged J, Kopp R, Haarh P. Is initial (24 hours) lavage necessary in treatment of CAPD peritonitis? Perit Dial Int 1991; 11(1): 38M2.
34. Coban E, Ozdogan M, Tuncer M, Bozcuk H, Ersoy F. The value of low-dose intraperitoneal immunoglobulin administration in the treatment of peritoneal dialysis-related peritonitis. J Nephrol 2004; 17(3): 427-430.
35. Kan GW, Thomas MA, Heath CH. A 12-month review of peritoneal dialysis-related peritonitis in Western Australia:is empiric vancomycin still indicated for some patients? Perit Dial Int 2003; 23(5): 465-468.
36. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C et al. Peritoneal dialysis-related infections recommendations:2005 update. Perit Dial Int 2005; 25(2): 107-131.
37. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents to prevent peritonitis in peritoneal dialysis:a systematic review of randomized controlled trials. Am J Kidney Dis 2004; 44(4): 591-603.
38. Daly CD, Campbell MK, MacLeod AM, Cody DJ, Vale LD, Grant AM et al. Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. Nephrol Dial Transplant 2001; 16(2): 341-347.
39. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Catheter-related interventions to prevent peritonitis in peritoneal dialysis:a systematic review of randomized, controlled trials. J Am Soc Nephrol 2004; 15(10): 2735-2746.
40. Wiggins K, Craig J, Johnson D, Strippoli G. Treatment for Peritoneal Dialysis-Associated Peritonitis. John Wiley & Sons, Ltd., New York, 2005.
41. Wiggins K, Johnson D, Craig J, Strippoli G. A systematic review of trials of peritoneal dialysis-associated treatment (abstract). Annual Scientific Meeting of American Society of Nephrology. Philadelphia, 2005.
42. Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16(2): 539-545.
43. Davey P, Craig AM, Hau C, Malek M. Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial. J Antimicrob Chemother 1999; 43(1): 105-112.
44. Johnson DW, van Eps C, Mudge DW, Wiggins KJ, Armstrong K, Hawley CM et al. Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. J Am Soc Nephrol 2005; 16(5): 1456-1462.
45. Bennet-Jones D, Martin J, Barratt A, Duffy T, Naish P, Aber G. Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD. Adv Perit Dial 1998; 4: 147-150.
46. Gadallah MF, Ramdeen G, Torres C, Mignone J, Patel D, Mitchell L et al. Preoperative vancomycin prophylaxis for newly placed peritoneal dialysis catheters prevents postoperative peritonitis. Adv Perit Dial 2000; 16: 199-203.
47. Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters. Scand J Urol Nephrol 1992; 26(2): 177-180.
48. Wikdahl AM, Engman U, Stegmayr BG, Sorenssen JG. One-dose cefurox-ime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. Nephrol Dial Transplant 1997; 12(1): 157-160.
49. Lo WK, Chan CY, Cheng SW, Poon JF, Chan DT, Cheng IK. A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28(4): 549-552.
50. Wilson AP, Lewis C, O'Sullivan H, Shetty N, Neild GH, Mansell M. The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD). J Hosp Infect 1997; 35(4): 287-293.
51. Nolph K, Prowant B, Serkes K, et al. A randomized multicenter clinical trial to evaluate the effects of an ultraviolet germicidal system on peritonitis rate in continuous ambulatory peritoneal dialysis. Perit Dial Bull 1985; 1: 19-24.
52. Poole-Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC. Vaccination for prevention of CAPD associated staphylococcal infection:results of a prospective multicentre clinical trial. Clin Nephrol 1991; 35(5): 198-206.
53. Owen JE, Walker RG, Lemon J, Brett L, Mitrou D, Becker GJ. Randomized study of peritonitis with conventional versus O-set techniques in continuous ambulatory peritoneal dialysis. Perit Dial Int 1992; 12(2): 216-220.
54. Ansell D, Feest T. UK Renal Registry Report 1998. Bristol, United Kingdom, 1998.
55. Johnson D. Peritoneal dialysis In:McDonald S, Russ G, editors, ANZ-DATA Registry Report 2003. Adelaide, 1998; 39-54.
56. Bro S, Bjorner JB, Tofte-Jensen P, Klem S, Almtoft B, Danielsen H et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 1999; 19(6): 526-533.
57. De Fijter C, Oe P, Nauta JJ, van der Meulen J, ter Wee PM, Snoek FJ et al. A prospective randomised trial comparing the peritonitis incidence of CAPD and Y-connector (CAPD-Y) with continuous cyclic peritoneal dialysis (CCPD). Adv Perit Dial 1991; 7: 186-189.
58. Flanigan MJ, Hochstetler LA, Langholdt D, Lim VS. Continuous ambu-latoryperitoneal dialysis catheter infections:diagnosis and management. Perit Dial Int 1994; 14(3): 248-254.
59. Plum J, Artik S, Busch T, Sahin K, Grabensee B. Oral versus intraperi-toneal application of clindamycin in tunnel infections:a prospective, randomised study in CAPD patients. Perit Dial Int 1997; 17: 486-492.
60. Flanigan MJ, Lim VS. Initial treatment of dialysis associated peritonitis:a controlled trial of vancomycinversus cefazolin. Perit Dial Int 1991; 11(1): 31-37.
61. Khairullah Q, Provenzano R, Tayeb J, Ahmad A, Balakrishnan R, Morrison L. Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients. Perit Dial Int 2002; 22(3): 339-344.
62. Cheng IK, Chan CY, Wong WT, Cheng SW, Ritchie CW, Cheung WC et al. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13(Suppl 2): S351-S354.
63. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Entero-coccus. Emerg Infect Dis 2002; 8(8): 802-807.
64. Oprea SF, Zaidi N, Donabedian SM, Balasubramaniam M, Hershberger E, Zervos MJ. Molecular and clinical epidemiologyofvancomycin-resistant Enterococcus faecalis. J Antimicrob Chemother 2004; 53(4): 626-630.
65. Lui SL, Cheng SW, Ng F, Ng SY, Wan KM, Yip T et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis:effect on residual renal function. Kidney Int 2005; 68(5): 2375-2380.
66. Bennett-Jones DN, Russell GI, Barrett A. A comparison between oral ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis. J Antimicrob Chemother 1990; 26(Suppl F): 73-76.
67. Boeschoten EW, Rietra PJ, Krediet RT, Visser MJ, Arisz L. CAPD peritonitis:a prospective randomized trial of oral versus intraperitoneal treatment with cephradine. J Antimicrob Chemother 1985; 16(6): 789-797.
68. Chan MK, Cheng IK, Ng WS. A randomized prospective trial of three different regimens of treatment of peritonitis in patients on continuous ambulatoryperitoneal dialysis. Am J Kidney Dis 1990; 15(2): 155-159.
69. Cheng IK, Chan CY, Wong WT. A randomised prospective comparison of oral of loxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1991; 11(1): 27-30.
70. Gucek A, Bren AF, Lindic J, Hergouth V, Mlinsek D. Is monotherapywith cefazolin or of loxacin an adequate treatment for peritonitis in CAPD patients? Adv Perit Dial 1994; 10: 144-146.
71. Lye WC, Lee EJ, van der Straaten J. Intraperitoneal vancomycin/oral pe-floxacin versus intraperitoneal vancomycin/gentamicin in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int 1993; 13(Suppl 2): S348-S350.
72. Tapson JS, Orr KE, George JC, Stansfield E, Bint AJ, Ward MK. A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis. J Antimicrob Chemother 1990; 26(Suppl F): 63-71.
73. Bailie GR, Morton R, Ganguli L, Keaney M, Waldek S. Intravenous or intraperitoneal vancomycin for the treatment of continuous ambulatory peritoneal dialysis associated gram-positive peritonitis? Nephron 1987; 46(3): 316-318.
74. Cheng I, Lui S, Fang G, Chau P, Cheng S, Chiu F et al. A randomised prospective comparison of oral versus intraperitoneal of loxacin as the primary treatment of CAPD peritonitis. Nephrology 1997; 3: 431-435.
75. Grabe DW, Bailie GR, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal ceftazidime. Am J Kidney Dis 1999; 33(1): 111-117.
76. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19(1): 65-70.
77. Boyce NW, Wood C, Thomson NM, Kerr P, Atkins RC. Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis:a prospective, randomized comparison of intermittent v continuous therapy. Am J Kidney Dis 1988; 12(4): 304-306.
78. Lye WC, Wong PL, van der Straaten JC, Leong SO, Lee EJ. A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Adv Perit Dial 1995; 11: 179-181.
79. Schaefer F, Klaus G, Muller-Wiefel DE, Mehls O. Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS). J Am Soc Nephrol 1999; 10(1): 136-145.
80. Manley HJ, Bailie GR. Treatment of peritonitis in APD:pharmacokinetic principles. Semin Dial 2002; 15(6): 418-421.
81. Gadallah MF, Tamayo A, Sandborn M, Ramdeen G, Moles K. Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 233-236.
82. Tong MK, Leung KT, Siu YP, Lee KF, Lee HK, Yung CY et al. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis. J Nephrol 2005; 18(2): 204-208.
83. Williams AJ, Boletis I, Johnson BF, Raftery AT, Cohen GL, Moorhead PJ et al. Tenckhoff catheter replacement or intraperitoneal urokinase:a randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis. Perit Dial Int 1989; 9(1): 65-67.